drugset / Trial / NCT06935175

A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer

NCT06935175

Phase 2 Not yet recruiting 53 enrolled Shanghai Zhongshan Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study was designed to evaluate the efficacy and safety of SHR-1826 monotherapy or in combination with immunotherapy in the treatment of advanced hepatocellular cancer patients.

Timeline

Start
2025-05-01
Primary completion
2027-05-31
Completion
2028-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-1826 Unknown